Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.41 |
| ▸ | GIPR | P48546 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659853 | 0.90 | MAPT (0.44) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| SCHEMBL4088222 | 0.73 | GCGR (0.43) | GCGRGIPRRAB9AHTT | |
| SCHEMBL15427597 | 0.64 | THRB (0.66) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL11142389 | 0.64 | ALDH1A1 (0.71) | MEN1KMT2APOLBGAAALDH1A1 | |
| SCHEMBL4238428 | 0.59 | RXRA (0.43) | POLBSMN1; SMN2ALDH1A1RXRARXRB | |
| SCHEMBL24328826 | 0.59 | CYP1A2 (0.41) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| SCHEMBL24327424 | 0.59 | MTOR (0.48) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| SCHEMBL3239026 | 0.58 | ALDH1A1 (0.56) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| 4-Methylbenzoic Acid SCHEMBL30542968 | 0.58 | ALDH1A1 (0.85) | MEN1KMT2APOLBGAASMN1; SMN2 | |
| SCHEMBL13719791 | 0.58 | NPC1 (0.70) | MEN1KMT2ASMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2484/4885KMT2A 3172/4885POLB 4537/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2484/4885KMT2A 3172/4885POLB 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.